Akdes Serin Harmancı

This study shows that targeting SAGA/ATAC complexes disrupts chromatin regulation and cholesterol metabolism in diffuse midline glioma, leading to reduced tumor growth.

This study shows that combining CDK9 inhibitors with neuropsychiatric drugs reduces diffuse midline glioma growth by altering H3 dopaminylation and CaMKII signaling.

This study shows common AAV vectors transduce multiple human brain cell types in organotypic slices, with astrocytes showing the most protein expression, and introduces a pipeline for optimizing AAV vectors.

This study shows that mutant IDH impairs PDGFB's chromatin binding, leading to chromosome instability and accelerated gliomagenesis.

This study identifies NF2 loss-of-function and hypoxia as drivers of radiation resistance in Grade 2 meningiomas through genetic, histopathological, and transcriptional analyses.

This study uses scRNA-seq data to identify developmental-like cell states in brain tumors, suggesting potential cells of origin for medulloblastoma, glioma, and diffuse midline glioma.

The paper evaluates the transcriptional stability of cell types in ex vivo human brain tissue cultures over 14 days using single-nucleus RNA sequencing.

The paper identifies hybrid cells in human glioma with both neuronal and glial electrophysiological and transcriptomic features using Patch-sequencing and a new computational tool.

This study develops CLIPPR, an algorithm that integrates single-cell and bulk RNA-seq data to improve meningioma classification and resolve benign-malignant confusion.

This study shows inhibitory neuron activity and astrocytic GABABR are necessary for astrocyte morphogenesis, with region-specific transcription factors regulating this process.

XCVATR identifies and characterizes variant impact on embeddings of single-cell and bulk RNA-seq samples by detecting local variant enrichment in embedding space.

scRegulocity detects local RNA velocity patterns in single-cell RNA-seq embeddings to identify regulatory changes and cell state transitions.

CaSpER identifies and analyzes CNV events in single-cell and bulk RNA sequencing data, revealing novel sub-clones and therapeutic targets in GBM.